Is Incyte Stock a Good Investment?
Incyte Investment Advice | INCY |
- Examine Incyte's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Incyte's leadership team and their track record. Good management can help Incyte navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Incyte's business and its evolving consumer preferences.
- Compare Incyte's performance and market position to its competitors. Analyze how Incyte is positioned in terms of product offerings, innovation, and market share.
- Check if Incyte pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Incyte's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Incyte stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Incyte is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Incyte Stock
Researching Incyte's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The book value of Incyte was currently reported as 16.45. The company has Price/Earnings To Growth (PEG) ratio of 0.6. Incyte had not issued any dividends in recent years. The entity had 2:1 split on the 1st of September 2000.
To determine if Incyte is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Incyte's research are outlined below:
| Incyte has a strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Innovent Receives Approval of DOVBLERON by Chinas National Medical Products Administration |
Incyte Quarterly Liabilities And Stockholders Equity |
|
Incyte uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Incyte. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Incyte's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Incyte's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Incyte's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-10-31 | 2017-09-30 | 0.07 | 0.08 | 0.01 | 14 | ||
2017-08-01 | 2017-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2015-04-30 | 2015-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
1998-07-14 | 1998-06-30 | 0.09 | 0.1 | 0.01 | 11 | ||
1997-04-17 | 1997-03-31 | 0.03 | 0.02 | -0.01 | 33 | ||
1996-07-25 | 1996-06-30 | -0.03 | -0.04 | -0.01 | 33 | ||
2015-08-04 | 2015-06-30 | -0.11 | -0.09 | 0.02 | 18 | ||
1999-02-03 | 1998-12-31 | 0.1 | 0.12 | 0.02 | 20 |
Know Incyte's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Incyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Incyte backward and forwards among themselves. Incyte's institutional investor refers to the entity that pools money to purchase Incyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-09-30 | 2.2 M | Bellevue Group Ag | 2024-09-30 | 2.2 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.1 M | Norges Bank | 2024-06-30 | 2.1 M | Mizuho Securities Usa Inc | 2024-09-30 | 2 M | Legal & General Group Plc | 2024-09-30 | 1.7 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.6 M | Northern Trust Corp | 2024-09-30 | 1.5 M | Jane Street Group Llc | 2024-06-30 | 1.5 M | Baker Bros Advisors Lp | 2024-09-30 | 30.7 M | Blackrock Inc | 2024-06-30 | 21.4 M |
Incyte's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 13.26 B.Market Cap |
|
Incyte's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.11 | 0.12 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.12 | 0.19 |
Determining Incyte's profitability involves analyzing its financial statements and using various financial metrics to determine if Incyte is a good buy. For example, gross profit margin measures Incyte's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Incyte's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Incyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Incyte. Check Incyte's Beneish M Score to see the likelihood of Incyte's management manipulating its earnings.
Evaluate Incyte's management efficiency
Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 23.21 | 24.37 | |
| Tangible Book Value Per Share | 21.96 | 23.06 | |
| Enterprise Value Over EBITDA | 11.82 | 12.41 | |
| Price Book Value Ratio | 2.71 | 2.84 | |
| Enterprise Value Multiple | 11.82 | 12.41 | |
| Price Fair Value | 2.71 | 2.84 | |
| Enterprise Value | 12.7 B | 13.4 B |
Incyte showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 0.71 |
Basic technical analysis of Incyte Stock
As of the 23rd of December, Incyte retains the Downside Deviation of 2.36, market risk adjusted performance of 0.0657, and Risk Adjusted Performance of 0.0307. Incyte technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Incyte's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Incyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Incyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Incyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Herve Hoppenot over three weeks ago Disposition of 4961 shares by Herve Hoppenot of Incyte at 64.25 subject to Rule 16b-3 | ||
Trotta Matteo over three weeks ago Acquisition by Trotta Matteo of 2646 shares of Incyte subject to Rule 16b-3 | ||
Flannelly Barry P over a month ago Acquisition by Flannelly Barry P of 2256 shares of Incyte at 68.62 subject to Rule 16b-3 | ||
Sheila Denton over two months ago Disposition of 2136 shares by Sheila Denton of Incyte at 67.63 subject to Rule 16b-3 | ||
Thomas Tray over three months ago Disposition of 382 shares by Thomas Tray of Incyte at 63.37 subject to Rule 16b-3 | ||
Stein Steven H over three months ago Disposition of 11608 shares by Stein Steven H of Incyte at 60.63 subject to Rule 16b-3 | ||
Baker Bros. Advisors Lp over six months ago Acquisition by Baker Bros. Advisors Lp of 543 shares of Incyte subject to Rule 16b-3 | ||
Whitfield Roy A over a year ago Sale by Whitfield Roy A of 30000 shares of Incyte |
Incyte's Outstanding Corporate Bonds
Incyte issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Incyte uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Incyte bonds can be classified according to their maturity, which is the date when Incyte has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Incyte's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Incyte's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0307 | |||
| Market Risk Adjusted Performance | 0.0657 | |||
| Mean Deviation | 1.66 | |||
| Semi Deviation | 2.23 | |||
| Downside Deviation | 2.36 | |||
| Coefficient Of Variation | 3324.46 | |||
| Standard Deviation | 2.55 | |||
| Variance | 6.49 | |||
| Information Ratio | 0.0174 | |||
| Jensen Alpha | 0.0401 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.0188 | |||
| Treynor Ratio | 0.0557 | |||
| Maximum Drawdown | 20.37 | |||
| Value At Risk | (3.22) | |||
| Potential Upside | 3.02 | |||
| Downside Variance | 5.56 | |||
| Semi Variance | 4.99 | |||
| Expected Short fall | (1.74) | |||
| Skewness | 1.02 | |||
| Kurtosis | 7.96 |
| Risk Adjusted Performance | 0.0307 | |||
| Market Risk Adjusted Performance | 0.0657 | |||
| Mean Deviation | 1.66 | |||
| Semi Deviation | 2.23 | |||
| Downside Deviation | 2.36 | |||
| Coefficient Of Variation | 3324.46 | |||
| Standard Deviation | 2.55 | |||
| Variance | 6.49 | |||
| Information Ratio | 0.0174 | |||
| Jensen Alpha | 0.0401 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.0188 | |||
| Treynor Ratio | 0.0557 | |||
| Maximum Drawdown | 20.37 | |||
| Value At Risk | (3.22) | |||
| Potential Upside | 3.02 | |||
| Downside Variance | 5.56 | |||
| Semi Variance | 4.99 | |||
| Expected Short fall | (1.74) | |||
| Skewness | 1.02 | |||
| Kurtosis | 7.96 |
Consider Incyte's intraday indicators
Incyte intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Incyte stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Incyte Corporate Filings
F4 | 17th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 21st of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F3 | 3rd of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Incyte Stock media impact
Far too much social signal, news, headlines, and media speculation about Incyte that are available to investors today. That information is available publicly through Incyte media outlets and privately through word of mouth or via Incyte internal channels. However, regardless of the origin, that massive amount of Incyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Incyte news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Incyte relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Incyte's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Incyte alpha.
Incyte Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Incyte can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Incyte Corporate Management
| Sheila JD | General VP | Profile | |
| Thomas Tray | Chief Finance | Profile | |
| Pamela Murphy | Vice Communications | Profile | |
| Paula Swain | Executive Resources | Profile | |
| Christine Chiou | Head Relations | Profile | |
| Michael Morrissey | Executive Operations | Profile | |
| PharmD MBA | Executive America | Profile |
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.